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Purpose. We aimed to investigate the factors influencing hemoglobin variability with inflammatory and nutritional parameters
and its associations with all-cause mortality among hemodialysis patients. Methods. One hundred and sixty-nine patients during
the entire 12 months were enrolled into the study. Fasting plasma glucose, creatinine, calcium, phosphorus, alkaline phosphatase,
parathyroid hormone (PTH), C-reactive protein (CRP), serum iron, serum iron-binding capacity, and transferrin saturation were
analyzed. We defined six groups: low, target range, high, low-amplitude fluctuation with low hemoglobin levels, low-amplitude
fluctuation with high hemoglobin levels, and high-amplitude fluctuation. Body mass index (BMI), malnutrition-inflammation
score (MIS), and Charlson Comorbidity Index were evaluated.Results.Hemoglobin variability was significantly correlated with age,
platelet count, and number of hospitalization instances and inversely correlated with erythropoietin dose per body surface area.
The coefficient of variation of hemoglobin showed a correlation with MIS and ferritin. The absolute level of hemoglobin showed a
negative correlation between PTH,CRP,MIS, number of hospitalization instances and a positive correlationwith albumin andBMI.
High, low, and target-range groups showed survival advantage compared to the other three groups. In regression analysis, age, CRP
levels, MIS, and BMI were the predictors of mortality. Conclusion. Inflammation and duration of anemia were the major predictors
of hemoglobin variability. High-amplitude fluctuation predicts highmortality; on the contrary low-amplitude fluctuations is related
to better survival. MIS was independently associated with mortality. This trial is registered with NCT03454906.
1. Introduction
Anemia is a common complication of chronic kidney dis-
ease (CKD). The introduction of erythropoiesis-stimulating
agents (ESA) has led to a dramatic reduction in blood trans-
fusion requirements and has been associated with improved
quality of life [1, 2]. Although the optimal target hemoglobin
concentration in CKD remains a matter of considerable
uncertainty, the European Best Practice Guidelines (EBPG)
recommended that the target hemoglobin level should be
defined on an individual basis, taking into account gender,
age, ethnicity, activity, and comorbid conditions [3].
Fluctuation in hemoglobin levels, known as hemoglobin
variability during treatment with ESA, is a well-documented
phenomenon [4]. Several factors have been found to affect
hemoglobin variability, including drug-related issues, such
as pharmacokinetic parameters, patient-related differences
in demographic characteristics, and factors affecting clinical
status, as well as clinical practice guidelines, treatment pro-
tocols, and reimbursement policies [5]. Inflammation is also
an important factor associated with hemoglobin variability,
and the consequences of persistent inflammatory activity
are far-reaching in affected patients. Lacson Jr. et al. [6]
reported that few patients maintained hemoglobin in the
target range in a study that measured variability in patients
with CKD. Overall, only 38.4% of patients had hemoglobin
levels between 11 and 12 g/dL, while 12.2%, 31.5%, and 30%
of patients had hemoglobin levels at 10, <11, and >12 g/dL,
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respectively. Ebben et al. measured hemoglobin levels in a
large cohort of patients for 6 months and found that only a
minority of patients (6.5%) had stable hemoglobin levels over
the study period with nearly 90% exhibiting some pattern of
hemoglobin fluctuation [7].
In the present study, we aimed to investigate factors
influencing hemoglobin variability with inflammatory and
nutritional parameters and the association of hemoglobin
variability with all-cause mortality among hemodialysis
patients.
2. Materials and Methods
This was a single-center study at a university teaching
hospital. Among 220 hemodialysis patients, 169 patients (107
males; aged 54.3 ± 14.5 years) during the entire 12 months
(January 2009 to January 2010) were enrolled into the study.
The dosage of ESA was assessed due to reimbursement
from our country as 150U/kg/week if hemoglobin level
was <11mg/dl and 75U/kg/week if hemoglobin level was
between 11 and 11.9mg/dl. ESA therapy was stopped when
hemoglobin level reached 12mg/dl. Intravenous iron sucrose
was prescribed if ferritin was <100 𝜇g/L or the transferrin
saturation (TSAT) was <20% and Hgb was below the target
range. Patients received 100mg intravenously over each of the
next 10HD treatments and then every 2weeks thereafter. Iron
waswithheld if ferritinwas>800𝜇g/L or theTSATwas>50%.
All patients’ standard clinical (age, gender, duration of
hemodialysis, and history of hospitalization) and biochem-
ical parameters were analyzed cross-sectionally. As part of
our quality assurance program, complete blood count and
biochemical parameters were checked during the monthly
clinic visit within this period. In all participants, a venous
blood sample was collected after an overnight fast to measure
the concentration of the following biochemical variables
using standard laboratory techniques: fasting plasma glucose
(FPG), creatinine, calcium, phosphorus, albumin, alkaline
phosphatase (ALP), parathyroid hormone (PTH) levels, C-
reactive protein (CRP), iron parameters (serum iron, serum
iron-binding capacity, and transferring saturation), and a
lipid profile (total cholesterol [C], HDL-C, TGs, and LDL-
C [low-density lipoprotein C; computed from Friedewald’s
formula]). All patients had a minimum of six hemoglobin
measurements within a 6-month period.They were excluded
if they either received a kidney transplant during this time
or had a blood transfusion during the baseline period.
Patients with serum ferritin < 100 𝜇g/L were also excluded
from the study because of reimbursement from our country.
We defined six groups of patients based on their overall
pattern of fluctuation to assess both the frequency and size
of fluctuations in hemoglobin levels over time: consistently
low (L; all 6months with low hemoglobin levels), consistently
within the target range (T; all 6 months with target-range
hemoglobin levels), consistently high (H; all 6 months with
high hemoglobin levels), low-amplitude fluctuation with low
hemoglobin levels (LAL; all 6 months with low or target-
range hemoglobin levels), low-amplitude fluctuation with
high hemoglobin levels (LAH; all 6 months with target-range
or high hemoglobin levels), and high-amplitude fluctuation
(HA; low, target-range, and high hemoglobin levels within
the 6-month period). ESA and iron therapy dosages were
calculated per month and cumulative dose per year.
The number of months that elapsed with hemoglobin <
11 g/dl was also calculated. Body weight and body mass index
(BMI; in kg/m2) were taken after the dialysis session. Height
was obtained from the patient’s chart. The malnutrition-
inflammation score (MIS) assessmentwas performed accord-
ing to the description byKalantar-Zadeh et al. [8]. It consisted
of medical history (weight changes, dietary intake, gas-
trointestinal symptoms, functional capacity, and presence of
comorbidities), physical examination (loss of subcutaneous
fat and muscle wasting), and laboratory parameters (serum
albumin and total iron-binding capacity). Each of the com-
ponents was scored from0 (normal) to 3 (severely abnormal).
The sum of all points gave the total MIS (maximum 30).
The Charlson Comorbidity Index (CCI) is based on ICD-
9 codes in claims data. It was designed as a measure of the
risk of 1- to 10-year mortality attributable to comorbidity in a
longitudinal study of general hospitalized patients.
This study was approved by Baskent University Institu-
tional Review Board and Ethics Committee (IRB approval
number: KA09/358).
2.1. Statistical Analyses. Statistical analyses were performed
by using SPSS software (Statistical Package for the Social
Sciences, version 11.0, SPSS Inc., Chicago, IL, USA). Nor-
mality of data was analyzed by using a Kolmogorov-Smirnov
test. All numerical variables with normal distribution were
expressed as means ± standard deviations (SD), while vari-
ables with skewed distributions were expressed as medians
and interquartile ranges (IR). Categorical variables were
expressed as percentages and compared by a chi-square
test. Normally distributed numeric variables were analyzed
by independent samples 𝑡-tests or one-way ANOVA (post
hoc Tukey) tests according to distribution normality. The
baseline variables used for analysis were similar to those
for survival analysis. A Kaplan–Meier analysis was used to
examine the effects of hemoglobin variability on all-cause
mortality and the time to ESRD. Descriptive statistics were
used to examine patient characteristics according to the six
hemoglobin variability categories of the first classification
system, andmortality rates were calculated for the categories.
A value of 𝑝 < 0.05 was considered statistically significant.
Descriptive statistics were used to examine patient character-
istics according to the six hemoglobin variability categories
of the first classification system, and mortality rates were
calculated for the categories.
3. Results
Demographic characteristics and mean values for laboratory
parameters of the study population during the 12-month
period are summarized in Table 1. Using the classification sys-
tem, the percentage of patients in each of the six groupswas as
follows: consistently low 21.8%, consistently within the target
range 24.8%, consistently high 7.6%, low-amplitude fluctua-
tion with low hemoglobin levels 13.0%, low-amplitude fluctu-
ation with high hemoglobin levels 9.4%, and high-amplitude
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Table 1: Patient characteristics of hemoglobin variability.
Patient characteristics HA (𝑛: 39) High (𝑛: 13) Target (𝑛: 42) Low (𝑛: 37) LAH (𝑛: 16) LAL (𝑛: 22)
% of total (𝑛: 169) 23.4 7.6 24.8 21.8 9.4 13
Age (years) (mean ± SD) 54.6 ± 14.0 47.4 ± 8.3 57.8 ± 13.3 51.7 ± 18.3 53.8 ± 12.2 55.2 ± 15.1
Gender (male) (%) 25 (44.7%) 7 (7.6%) 31 (18.3%) 23 (43.6%) 16 (4.7%) 13 (7.6%)
CKD etiology
Diabetes mellitus 3 2 3 4 2 3
Hypertension 6 3 9 7 3 4
PCKD 3 1 3 4 2 3
Unknown etiology 10 2 9 7 3 5
Others 17 5 18 15 6 7
BMI (kg/m2) 23.3 ± 5.5 22.7 ± 3.7 22.4 ± 3.1 21.7 ± 4.8 23.3 ± 4.3 22.4 ± 4.5
Duration of dialysis (years) (mean ± SD) 10.0 ± 5.9 10.2 ± 4.9 9.0 ± 5.7 9.2 ± 5.2 10.0 ± 7.1 5.8 ± 4.7
HA: high-amplitude fluctuation; LAH: low-amplitude fluctuation with high hemoglobin; LAL: low-amplitude fluctuation with low hemoglobin; BMI: body
mass index; CKD: chronic kidney disease; PCKD: polycystic kidney disease; SD: standard deviation.
Table 2: Biochemical parameters and medications of hemoglobin variability.
Patient characteristics HA (𝑛: 39) High (𝑛: 13) Target (𝑛: 42) Low (𝑛: 37) LAH (𝑛: 16) LAL (𝑛: 22) 𝑝
Hemoglobin (g/dl) 10.7 ± 0.7 12.7 ± 0.8 11.1 ± 0.4 9.9 ± 0.8 12.2 ± 1.0 9.6 ± 0.6 0.001
Hb-var (g/dl)∗ 1 (0.4) 0.7 (0.3) 0.8 (0.3) 0.8 (0.2) 1 (0.1) 0.9 (0.2) 0.001
Maximum Hb-var (g/dl)∗ 4 (1.5) 2.4 (1.2) 2.5 (0.8) 2.6 (1.3) 3.9 (1.1) 3.6 (0.8) 0.001
Coefficient of Hb-var∗ 9.3 (4.1) 5.9 (2.8) 7.3 (2.7) 7.8 (2.8) 8.4 (1.5) 10.1 (2.9) 0.001
MCV (fl) 90.1 ± 3.9 89.1 ± 4.2 91.2 ± 4.6 91.5 ± 5.2 86.8 ± 6.8 88.1 ± 7.0 0.017
RDW (%)∗ 16.5 (2.4) 16.3 (2.2) 15.8 (1.5) 16.0 (1.2) 16.9 (1.6) 16.1 (1.6) 0.085
Leukocyte (×103/𝜇l) 7.0 ± 1.7 6.4 ± 1.3 6.7 ± 1.6 5.9 ± 1.7 7.3 ± 2.1 6.9 ± 1.6 0.05
Calcium (mg/dl) 9.4 ± 0.6 9.0 ± 0.6 9.2 ± 0.6 9.2 ± 0.8 9.2 ± 0.9 8.8 ± 0.6 0.135
Phosphate (mg/dl) 5.7 ± 1.5 5.3 ± 0.4 5.0 ± 1.2 5.1 ± 1.4 5.0 ± 1.1 5.1 ± 1.0 0.239
Albumin (g/dl) 4.0 ± 0.3 4.3 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.2 ± 0.6 4.1 ± 0.4 0.144
CRP (mg/l)∗ 9.7 (13) 4.7 (6) 9.7 (15) 7.6 (14) 11.2 (10) 7.5 (22) 0.744
Transferrin saturation%∗ 29.7 (12) 35.5 (14) 32.3 (13) 29.2 (23) 28.5 (17) 29.0 (17) 0.907
Ferritin (𝜇g/l)∗ 275 (400) 124 (86) 310 (222) 382 (298) 196 (248) 462 (400) 0.001
PTH (pg/ml)∗ 445.7 (728) 303.7 (400) 281.3 (508) 491.2 (1078) 214.4 (515) 299.7 (401) 0.118
URR% 66.2 ± 5.3 65.4 ± 4.6 66.1 ± 6.5 67.7 ± 6.7 64.4 ± 6.3 65.5 ± 8.5 0.600
MIS∗ 7 (4) 5 (5) 7 (4) 6 (3.5) 7 (2.8) 7.5 (4) 0.471
ESA total dose per body weight (U/kg)∗ 3.3 (3.4) 0.3 (0.6) 3.0 (2.4) 4.9 (1.4) 0.5 (1.6) 5.1 (2.1) 0.001
Iron per body weight (mg/kg)∗ 15.7 (25) 14.7 (27) 13.4 (16) 16.5 (19) 18.2 (19) 11.7 (20) 0.167
Months of hb < 11 g/dl 6.5 ± 2.3 0.5 ± 0.6 4.3 ± 2.0 9.9 ± 1.7 2.2 ± 2.4 10.4 ± 1.2 0.001
10 year survival∗ 21 (77) 21 (56) 21 (77) 53 (76) 21 (69) 53 (77) 0.851
HA: high-amplitude fluctuation; LAH: low-amplitude fluctuation with high hemoglobin; LAL: low-amplitude fluctuation with low hemoglobin; Hb-var
(hemoglobin variability); MCV: mean corpuscular volume: RDW: red blood cell distribution width; CRP: C-reactive protein; PTH: parathyroid hormone;
URR: urea reduction ratio; MIS: malnutrition-inflammation score; ESA: erythropoiesis-stimulating agents. ∗Median (Interquartile range); other results are
given as mean ± standard deviation.
fluctuation 23.4%. Among these six groups, there was no sig-
nificant difference with respect to age, duration of hemodial-
ysis, urea reduction ratio, serum PTH, calcium, phosphorus,
albumin, iron, and transferrin saturation levels.
The percentage of patients with mean hemoglobin con-
centration < 11 g/dl was 60.4%. Mean hemoglobin levels
differed significantly by gender (10.9 ± 1.2 g/dl [men] versus
10.4 ± 0.96 g/dl [women], 𝑝 = 0.006). The minimum
and maximum dosages of ESA were 25U/kg/week and
150U/kg/week, respectively. The median dosages of iron
therapy per bodyweightwere 15.7 (25), 14.7 (27), 13.4 (16), 16.5
(19), 18.2 (19), and 11.7 (20) mg/dl; BMI levels were 23.3 ± 5.5,
22.7±3.7, 22.4±3.1, 21.7±4.8, 23.3±4.3, and 22.4±4.5 kg/m2;
MIS levels were 7 (4), 5 (5), 7 (4), 6 (3.5), 7 (2.8), and 7.5 (4) in
patient groups with high-amplitude fluctuation, high, target,
low, and low-amplitude fluctuation with high hemoglobin
level, and low-amplitude fluctuation with low hemoglobin
level, respectively (Table 2).
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Table 3: Demographic characteristics, biochemical parameters, and medications of patients.
Exitus (𝑛: 31) Alive (𝑛: 138) 𝑝 value
Age (years) 60.6 ± 20.0 53.4 ± 13.4 0.027
Gender (male) 27 (15.9%) 96 (56.8%) 0.248
Duration of hemodialysis (years) 7.6 ± 5.4 9.5 ± 5.7 0.121
Hemoglobin (g/dl) 10.6 ± 1.03 10.8 ± 1.2 0.530
Hb-var (g/dl)∗ 0.94 (0.25) 0.89 (0.26) 0.578
Maximum Hb-var (g/dl)∗ 3.2 (1.7) 3.3 (1.7) 0.565
Coefficient of Hb-var∗ 8.8 (3.1) 8.4 (3.0) 0.429
RDW (%)∗ 16.2 (1.6) 16.3 (2) 0.733
Leukocyte (×103/𝜇l) 7.0 ± 1.7 6.6 ± 1.7 0.354
MCV (fl) 89.7 ± 4.9 90.1 ± 5.5 0.788
Serum Iron (mg/dl)∗ 53.5 (16.3) 58.2 (23.2) 0.206
Transferrin saturation (%)∗ 29.7 (11.7) 29.7 (18.3) 0.301
Ferritin (𝜇g/l)∗ 344.2 (297.7) 305.3 (317.1) 0.478
PTH (pg/ml)∗ 252.1 (419) 415 (699) 0.092
Calcium (mg/dl) 9.1 ± 0.6 9.1 ± 0.7 0.988
Phosphate (mg/dl) 5.1 ± 1.2 5.2 ± 1.3 0.615
Albumin (g/dl) 4.0 ± 0.3 4.2 ± 0.4 0.150
CRP (mg/l)∗ 16.7 (21.0) 8.2 (11.4) 0.008
URR (%) 66.5 ± 5.5 66.0 ± 6.6 0.693
MI˙S∗ 8 (3) 6 (3) 0.002
ESA total dose per body weight (U/kg) ∗ 4.1 (2.3) 3.1 (3.8) 0.066
I˙ron per body weight (mg/kg) ∗ 13.2 (23.1) 15.7 (21.5) 0.542
Months of hb < 11 g/dl 6.9 ± 3.1 6.2 ± 3.8 0.379
BMI (kg/m2) 21.0 ± 3.8 23.0 ± 4.5 0.046
10 year survival∗ 2 (37) 21 (75) 0.011
HA: high-amplitude fluctuation; LAH: low-amplitude fluctuation with high hemoglobin; LAL: low-amplitude fluctuation with low hemoglobin; Hb-var
(hemoglobin variability);MCV:mean corpuscular volume; RDW: red blood cell distribution width; CRP: C-reactive protein; PTH: parathyroid hormone; URR:
urea reduction ratio; MIS: malnutrition-inflammation score; ESA: erythropoiesis-stimulating agents; BMI: body mass index, ∗Median (interquartile range)
other results are given as mean ± standard deviation.
The absolute level of hemoglobin showed a negative
correlation between PTH, CRP, MIS, and number of hospi-
talizations (𝑝: 0.028, 𝑝: 0.004, 𝑝: 0.009, and 𝑝: 0.008, resp.)
and a positive correlation with albumin and BMI (𝑝: 0.007
and 𝑝: 0.009, resp.). Hemoglobin variability was significantly
correlated with age (𝑝: 0.007), platelet count (𝑝: <0.001),
and the number of hospitalizations (𝑝: 0.006) and inversely
correlated with erythropoietin dose per body surface area (𝑝:
0.001). The coefficient of variation of hemoglobin showed
a positive correlation with MIS and ferritin (𝑝: 0.046 and
𝑝: 0.026). The duration of dialysis, low levels of leucocyte,
ferritin, and CRP, and high doses of erythropoietin were
noted as effecting parameters for hemoglobin > 11 g/dl (𝑝:
0.002, 𝑝: 0.005, 𝑝: <0.001, 𝑝: 0.042, and 𝑝: 0.001, resp.).
The number of months elapsed with hemoglobin < 11 g/dl
was inversely correlated with the duration of hemodialysis,
hematocrit, albumin, and body weight (𝑝: 0.002, p: <0.001,
𝑝: 0.003, and 𝑝: 0.040, resp.) and significantly correlated with
ferritin, PTH, total erythropoietin dose, MIS, and number of
hospitalizations (p: <0.001, 𝑝: 0.38, p: <0.001, 𝑝: 0.013, and 𝑝:
0.007, resp.). In addition, the number of months elapsed with
hemoglobin < 11 g/dl was significantly different in these six
groups as the lowest in the consistently high group (0.5 ± 0.6
months) and the highest in low-amplitude fluctuation with
high hemoglobin levels (10.4 ± 1.2 months) (𝑝 = 0.001).
Kaplan–Meier analysis showed a significant difference asso-
ciated with mortality in each of the hemoglobin variability
groups. High, low, and target-range groups showed a survival
advantage compared with the low-amplitude fluctuation with
high hemoglobin levels, low-amplitude fluctuation with low
hemoglobin levels, and high-amplitude fluctuation groups
(100%, 94.1%, 91.4%, 88%, 70.8%, and 69.4%, resp.; 𝑝 <
0.009) (Figure 1). In regression analysis, age, CRP levels,
MIS, and BMI were significantly important predictors of
mortality (𝑝: 0.027, 𝑝: 0.008, 𝑝: 0.002, and 𝑝: 0.046, resp.)
(Table 3).
4. Discussion
In the present study, we detected hemoglobin variability that
was significantly lower in patients in the high stable group
than in other groups. This difference may be a result of more
enhanced renal function in this group even though we did
not detect preserved renal function in patients because of
limitations of this study. Also, we found that hemoglobin
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Figure 1: Kaplan–Meier analysis showing significant difference
associated with mortality in each of the hemoglobin variability
groups. Consistently high (H), consistently low (L), consistently
within the target range (T) groups showed survival advantage
compared with low-amplitude fluctuation with high hemoglobin
levels (LAH), low-amplitude fluctuation with low hemoglobin levels
(LAL), and high-amplitude fluctuation (HA) groups (100%, 94.1%,
91.4%, 88%, 70.8%, and 69.4%, resp.; 𝑝 < 0.009).
variability has a modest association with morbidity and all-
cause mortality in erythropoietin-treated dialysis patients.
Although the mechanism of hemoglobin variability remains
uncertain, patients treated with ESA pharmacologic features
and dosing of ESA are believed to lead to a cyclical pattern
of hemoglobin levels within the recommended range [9]. A
study showed that only about 5% of CKDpatientsmaintained
target levels of hemoglobin after a fewmonths of observation
[10]. Another study reported that over 90% of patients
experienced hemoglobin cycling [11]. In the literature, studies
concerning hemoglobin variability and its association with
mortality administered an unlimited ESA dosage to patients.
Conversely, in our study, we used stable doses and limited
ESA therapy because of medical policy.
The present study also evaluated the relationship between
ESA dosage per body weight in specific variability groups.
The results were not conflicting with previous studies [12]
as ESA doses were highest and increased over time in
patients with consistently low hemoglobin levels. Also, doses
were lower and decreased in patients with consistently high
hemoglobin levels. ESA dose requirements were the lowest
for patients with hemoglobin levels consistently within the
high stable group. When compared with previous studies,
we used relatively lower doses of ESA, and we believe that
hemoglobin variability patterns were not related to ESA
dosage but might be a result of both intermittent inflamma-
tion and dietary factors.
The CHOIR [13] and TREAT [14] trials also showed
that not ESA itself but its response rates are predictive for
mortality risk factors. In our study, patients in the high stable
group had the lowest mortality rate, whereas patients in
the high-amplitude fluctuation and low stable groups had
the highest mortality rates although hemoglobin variability
values did not show significance between deceased or alive
patients. This result was not surprising because it has been
recognized that more than 50% of patients with CKD have
an activated inflammatory response, as shown by increased
levels of CRP and other proinflammatory cytokines [15].
Evidence suggests that inflammation is an important fac-
tor associated with hemoglobin variability and the CRP level
is a good predictor for patients with less stable hemoglobin
levels in CKD patients [4]. The studies by Dellanna et al. and
Barany et al. both found a significant correlation between
hemoglobin variation and CRP values [16, 17]. In our study,
patients in the high stable group had lower serum leucocyte
and CRP levels that supported both lower inflammatory
processes and lower inflammation-related mortality rates.
These results provide supporting evidence that inflammation
can trigger hemoglobin variability. Thus, ESA dosage should
be revised, and patients should be followed closely in the pres-
ence of inflammatory conditions. Moreover, inflammation
is closely related to protein-energy malnutrition in dialysis
patients and the combination of these two conditions, known
as the malnutrition-inflammation complex syndrome, is fre-
quently observed in dialysis patients [18]. The inflammatory
and nutritional status can be evaluated by the malnutrition-
inflammation score (MIS). Our results support previous
studies demonstrating that serum CRP and MIS were pre-
dictive for both morbidity and mortality [19]. In addition,
because we used limited ESA therapy at a maximum of
150U/kg/week, we did not observe any mortality associated
with complications of hemoglobin overshooting, including
hypertension, high platelet counts, and thrombotic events
[20].
In Eckardt et al.’s study, among 5,037 hemodialysis
patients, low levels of hemoglobin (<11 g/dl) were established
as an increased risk for death and is similar to our results.
Furthermore, a lower body mass index and the timing of
hemoglobin values < 11 g/dl were both detected as predictors
of mortality of hemoglobin variability supporting our study
[21]. Another study by Gilbertson et al. with 159,720 HD
patients receiving rHuEPO found that patients who had a
low hemoglobin level (<11 g/dl) for the longest time had the
highest mortality risk [22]. These findings were also similar
to the results of our study. Our study has some limitations.
First, because of the impact of medical policy, ESA use was
limited. Second, our follow-up periodmaynot have been long
enough. Third, our data were collected retrospectively from
one medical center and obtained from a single database and,
therefore, reflect only a small sample.
In conclusion, our study demonstrates that both inflam-
mation and the duration of anemia were the major predictors
6 The Scientific World Journal
of hemoglobin variability. We also disproved that high-
amplitude fluctuations predict high mortality, but rather
that low-amplitude fluctuations are concerned with better
survival rates. In addition, hemoglobin variability itself did
not predict mortality; MIS and its effects on hemoglobin
variability were independently associated with mortality.
Therefore, a large randomized trial is needed to evaluate clin-
ical outcomes of hemoglobin variability in this population.
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